首页> 外文期刊>Obstetrical and gynecological survey >Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer--Where Does It Stand?A Review
【24h】

Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer--Where Does It Stand?A Review

机译:局部晚期宫颈癌的新辅助化疗——它在哪里?综述

获取原文
获取外文期刊封面目录资料

摘要

Platinum-based combination chemotherapy has been utilized in the neoadjuvant setting in locally advanced inoperable cervical cancer with the aim of improving response and survival. Neoadjuvant chemotherapy can be followed by either radiation therapy (RT) or by surgery in cases in which it seems to be appropriate. Available data indicate that preradiation chemotherapy yields no survival advantage over RT alone. However, presurgery chemotherapy may increase resectability in women with locally advanced cervical cancer to around 70 percent. Nonrandomized trials of neoadjuvant chemotherapy followed by surgery have shown some improvement in the outcome. Prospective randomized trials are needed to evaluate this approach as compared with RT alone and to define its precise role in locally advanced cervical cancer.
机译:铂类联合化疗已用于局部晚期无法手术的宫颈癌的新辅助治疗,目的是改善反应和生存率。新辅助化疗后可进行放疗 (RT) 或手术治疗(如果认为合适)。现有数据表明,与单独放疗相比,放疗前化疗没有生存优势。然而,术前化疗可能会将局部晚期宫颈癌女性的可切除性提高到70%左右。新辅助化疗后手术的非随机试验显示,结局有所改善。需要前瞻性随机试验来评估这种方法与单独放疗的比较,并确定其在局部晚期宫颈癌中的确切作用。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号